COVID-19 has radically transformed the valuations of vaccines in the stock market. Novavax has jumped from $4 a share to $164. Moderna has run up from $19 to $304. The vaccine stocks have run up the most because that subsector is still our best hope for defeating COVID-19 once and for all. But a lot of success has already been priced in by the market. Are there other biotech stocks that might run up 10 times in valuation?
Our roundtable of Fool contributors has three biotech nominees that might pull off a 10-bagger over the next several years. Here's why they like the stocks of 10x Genomics (NASDAQ: TXG) , Atea Pharmaceuticals (NASDAQ: AVIR) , and Doximity (NYSE: DOCS) .
Image Source: Getty Images.
For further details see:
3 COVID Stocks That Can Turn $1,000 Into $10,000